US LNG exports surge but will buyers in China turn up?
Neumora Therapeutics , Inc. (NASDAQ:NMRA) saw its Chief Strategy Officer, Aurora Daljit Singh, sell a portion of her holdings in the company. According to a recent SEC filing, Singh disposed of 8,565 shares of common stock on February 18, 2025. The shares were sold at a weighted average price of $1.6751, resulting in a total transaction value of approximately $14,347. The transaction comes as the stock trades near its 52-week low of $1.60, having declined 91% over the past year. InvestingPro data shows analyst price targets ranging from $4 to $30, suggesting potential upside despite recent weakness.
Following the sale, Singh retains direct ownership of 88,935 shares in the company. Additionally, Singh holds an indirect interest in 114,703 shares through the Aurora Family Trust. The sale was conducted under a pre-established Rule 10b5-1 trading plan, which was set up to automatically sell shares to cover applicable withholding obligations on vesting dates of restricted stock units. With a current market capitalization of $281 million and a strong liquidity position reflected in its 10.98 current ratio, InvestingPro analysis indicates the stock is currently undervalued based on its Fair Value model. Discover more insights and 13 additional ProTips in the comprehensive Pro Research Report.
In other recent news, Neumora Therapeutics has undergone significant leadership changes, with co-founder Paul L. Berns assuming the roles of CEO and chairman of the Board. These changes come as the company continues to focus on its pipeline of treatments for brain diseases. Neumora plans to discuss its financial results for the fourth quarter and full year of 2024 in early 2025. Meanwhile, the company has faced challenges with its lead drug candidate, navacaprant, after disappointing results from the KOASTAL-1 trial for major depressive disorder (MDD). Despite this setback, BofA Securities maintained a Buy rating on Neumora, though it significantly reduced the price target from $22.00 to $7.00. H.C. Wainwright and Mizuho (NYSE:MFG) Securities also reiterated positive ratings, with price targets of $30.00 and $20.00, respectively, expressing optimism for the ongoing KOASTAL-2 and KOASTAL-3 trials. However, RBC Capital Markets downgraded Neumora to Sector Perform, lowering the price target to $4.00 due to the trial’s failure. The company is expected to provide updates on the navacaprant program in the coming weeks, which may influence future assessments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.